

Signe Sørensen Torekov

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/851297/publications.pdf>

Version: 2024-02-01

47
papers

2,408
citations

331538

21
h-index

223716

46
g-index

48
all docs

48
docs citations

48
times ranked

4014
citing authors

#	ARTICLE	IF	CITATIONS
1	Celebrities in the heart, strangers in the pancreatic beta cell: Voltage-gated potassium channels $K_{v}7.1$ and $K_{v}11.1$ bridge long QT syndrome with hyperinsulinaemia as well as type 2 diabetes. <i>Acta Physiologica</i> , 2022, 234, e13781.	1.8	6
2	Sperm count is increased by diet-induced weight loss and maintained by exercise or GLP-1 analogue treatment: a randomized controlled trial. <i>Human Reproduction</i> , 2022, 37, 1414-1422.	0.4	34
3	Effects of vegan diets on cardiometabolic health: A systematic review and meta-analysis of randomized controlled trials. <i>Obesity Reviews</i> , 2022, 23, .	3.1	23
4	No effects of dapagliflozin, metformin or exercise on plasma glucagon concentrations in individuals with prediabetes: A post hoc analysis from the randomized controlled <i>PREED</i> trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 530-539.	2.2	9
5	Fat-Secreted Ceramides Regulate Vascular Redox State and Influence Outcomes in Patients With Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2494-2513.	1.2	59
6	Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. <i>New England Journal of Medicine</i> , 2021, 384, 1719-1730.	13.9	171
7	Age-dependent transition from islet insulin hypersecretion to hyposcretion in mice with the long QT-syndrome loss-of-function mutation <i>Kcnq1-A340V</i> . <i>Scientific Reports</i> , 2021, 11, 12253.	1.6	10
8	A Gut-Intrinsic Melanocortin Signaling Complex Augments L-Cell Secretion in Humans. <i>Gastroenterology</i> , 2021, 161, 536-547.e2.	0.6	10
9	Glucagon-like peptide-1 receptor agonists: the key to healthy weight loss maintenance?. <i>Cardiovascular Research</i> , 2021, 117, e120-e122.	1.8	3
10	Adults with pathogenic MC4R mutations have increased final height and thereby increased bone mass. <i>Journal of Bone and Mineral Metabolism</i> , 2020, 38, 117-125.	1.3	7
11	Glucagon acutely regulates hepatic amino acid catabolism and the effect may be disturbed by steatosis. <i>Molecular Metabolism</i> , 2020, 42, 101080.	3.0	66
12	Protocol for a single-centre, parallel-group, randomised, controlled, superiority trial on the effects of time-restricted eating on body weight, behaviour and metabolism in individuals at high risk of type 2 diabetes: the REstricted Eating Time (RESET) study. <i>BMJ Open</i> , 2020, 10, e037166.	0.8	13
13	Gain-of-function mutation in the voltage-gated potassium channel gene <i>KCNQ1</i> and glucose-stimulated hypoinsulinemia - case report. <i>BMC Endocrine Disorders</i> , 2020, 20, 38.	0.9	6
14	GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report. <i>Cell Reports Medicine</i> , 2020, 1, 100006.	3.3	22
15	Greater glucagon-like peptide-1 responses to oral glucose are associated with lower central and peripheral blood pressures. <i>Cardiovascular Diabetology</i> , 2019, 18, 130.	2.7	8
16	Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists. <i>Drug Safety</i> , 2019, 42, 957-971.	1.4	22
17	Protocol for a randomised controlled trial of the combined effects of the GLP-1 receptor agonist liraglutide and exercise on maintenance of weight loss and health after a very low-calorie diet. <i>BMJ Open</i> , 2019, 9, e031431.	0.8	11
18	Habitual physical activity is associated with lower fasting and greater glucose-induced GLP-1 response in men. <i>Endocrine Connections</i> , 2019, 8, 1607-1617.	0.8	5

#	ARTICLE	IF	CITATIONS
19	Evidence of a liver-α cell axis in humans: hepatic insulin resistance attenuates relationship between fasting plasma glucagon and glucagonotropic amino acids. <i>Diabetologia</i> , 2018, 61, 671-680.	2.9	76
20	Plasma Proteome Profiling Reveals Dynamics of Inflammatory and Lipid Homeostasis Markers after Roux-En-Y Gastric Bypass Surgery. <i>Cell Systems</i> , 2018, 7, 601-612.e3.	2.9	80
21	Patients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor Agonist. <i>Cell Metabolism</i> , 2018, 28, 23-32.e3.	7.2	88
22	Glucagon-like peptide-1 receptor agonists and cardiovascular disease: from LEADER to EXSCEL. <i>Cardiovascular Research</i> , 2018, 114, e70-e71.	1.8	6
23	Common variants in the hERG (KCNH2) voltage-gated potassium channel are associated with altered fasting and glucose-stimulated plasma incretin and glucagon responses. <i>BMC Genetics</i> , 2018, 19, 15.	2.7	12
24	Patients With Long-QT Syndrome Caused by Impaired <i>hERG</i> -Encoded K _v 11.1 Potassium Channel Have Exaggerated Endocrine Pancreatic and Incretin Function Associated With Reactive Hypoglycemia. <i>Circulation</i> , 2017, 135, 1705-1719.	1.6	33
25	Glucose ingestion causes cardiac repolarization disturbances in type 1 long QT syndrome patients and healthy subjects. <i>Heart Rhythm</i> , 2017, 14, 1165-1170.	0.3	8
26	Instrumentalization of Eating Improves Weight Loss Maintenance in Obesity. <i>Obesity Facts</i> , 2017, 10, 633-647.	1.6	23
27	Health care professionals from developing countries report educational benefits after an online diabetes course. <i>BMC Medical Education</i> , 2017, 17, 97.	1.0	23
28	Treatment with liraglutide may improve markers of CVD reflected by reduced levels of apoB. <i>Obesity Science and Practice</i> , 2017, 3, 425-433.	1.0	25
29	Glucagon-Like Peptide 1: A Predictor of Type 2 Diabetes?. <i>Journal of Diabetes Research</i> , 2017, 2017, 1-13.	1.0	21
30	Proteomics reveals the effects of sustained weight loss on the human plasma proteome. <i>Molecular Systems Biology</i> , 2016, 12, 901.	3.2	188
31	Insulin Resistance Is Accompanied by Increased Fasting Glucagon and Delayed Glucagon Suppression in Individuals With Normal and Impaired Glucose Regulation. <i>Diabetes</i> , 2016, 65, 3473-3481.	0.3	137
32	Weight loss and weight maintenance obtained with or without GLP-1 analogue treatment decrease branched chain amino acid levels. <i>Metabolomics</i> , 2016, 12, 1.	1.4	0
33	Successful weight loss maintenance includes long-term increased meal responses of GLP-1 and PYY36. <i>European Journal of Endocrinology</i> , 2016, 174, 775-784.	1.9	72
34	Glucose-Dependent Insulinotropic Polypeptide Is Associated With Lower Low-Density Lipoprotein But Unhealthy Fat Distribution, Independent of Insulin: The ADDITION-PRO Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 485-493.	1.8	46
35	Major rapid weight loss induces changes in cardiac repolarization. <i>Journal of Electrocardiology</i> , 2016, 49, 467-472.	0.4	12
36	GLP-1 Response to Oral Glucose Is Reduced in Prediabetes, Screen-Detected Type 2 Diabetes, and Obesity and Influenced by Sex: The ADDITION-PRO Study. <i>Diabetes</i> , 2015, 64, 2513-2525.	0.3	235

#	ARTICLE	IF	CITATIONS
37	GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 2909-2917.	1.8	116
38	Response to Comment on Fårhøj et al. GLP-1 Response to Oral Glucose Is Reduced in Prediabetes, Screen-Detected Type 2 Diabetes, and Obesity and Influenced by Sex: The ADDITION-PRO Study. <i>Diabetes</i> 2015;64:2513-2525. <i>Diabetes</i> , 2015, 64, e30-e31.	0.3	1
39	KCNQ1 Long QT Syndrome Patients Have Hyperinsulinemia and Symptomatic Hypoglycemia. <i>Diabetes</i> , 2014, 63, 1315-1325.	0.3	61
40	Therapies for inter-relating diabetes and obesity – GLP-1 and obesity. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 2487-2500.	0.9	37
41	Dose response of subcutaneous GLP-1 infusion in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2011, 13, 639-643.	2.2	21
42	Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential. <i>Obesity Reviews</i> , 2011, 12, 593-601.	3.1	50
43	Homozygous carriers of the G allele of rs4664447 of the glucagon gene (GCG) are characterised by decreased fasting and stimulated levels of insulin, glucagon and glucagon-like peptide (GLP)-1. <i>Diabetologia</i> , 2011, 54, 2820-2831.	2.9	16
44	Family and Population-Based Studies of Variation within the Ghrelin Receptor Locus in Relation to Measures of Obesity. <i>PLoS ONE</i> , 2010, 5, e10084.	1.1	18
45	Low Physical Activity Accentuates the Effect of the <i>FTO</i> rs9939609 Polymorphism on Body Fat Accumulation. <i>Diabetes</i> , 2008, 57, 95-101.	0.3	431
46	Association between Neuromedin U Gene Variants and Overweight and Obesity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 5057-5063.	1.8	54
47	Evidence of an Association Between the Arg72 Allele of the Peptide YY and Increased Risk of Type 2 Diabetes. <i>Diabetes</i> , 2005, 54, 2261-2265.	0.3	33